Modality
mAb
MOA
KRASG12Di
Target
BTK
Pathway
Epigenetic
Psoriasis
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
~Sep 2022
→ ~Dec 2023
Phase 3
~Mar 2024
→ ~Jun 2025
NDA/BLA
Sep 2025
→ Oct 2030
NDA/BLACurrent
NCT03503288
1,594 pts·Psoriasis
2025-09→2030-10·Not yet recruiting
1,594 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-204.6y awayPh3 Readout· Psoriasis
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2030-10-20 · 4.6y away
Psoriasis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03503288 | NDA/BLA | Psoriasis | Not yet recr... | 1594 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Pemitinib | Xenon Pharma | Preclinical | BTK |